Qiming Venture Partners | Connecting World-Class Science with Top Investors: Second Round of Startup Proposals Open for Inaugural S2S China Symposium
We sincerely invite top scientists to visit the S2SChina website and submit proposals, embarking on an accelerated journey from the lab to entrepreneurship.
The inaugural S2S (Science2Startup) China Symposium, co-hosted by RA Capital Management and Qiming Venture Partners, will take place on October 15, 2026, in Hangzhou, Zhejiang. As a premier entrepreneurship competition in the biotech space, the second call for proposals from China's top universities and research institutions (https://www.s2schina.com/) has entered its final countdown (deadline: April 30, 2026). ATLATL, the preferred partner, along with media strategic partners VBData, Yixuejie · Pharmaceutical Innovation, and PharmaDJ, will provide full support for the successful hosting of S2S in China.
S2S (Science2Startup) is a globally renowned life sciences entrepreneurship incubation platform. Founded in 2018 by F-Prime Capital, SV Health, and Atlas Venture, it has evolved into a core engine for global biotech innovation. S2S China is jointly initiated by RA Capital Management and Qiming Venture Partners. RA Capital Management is one of the most active asset management firms in global life sciences and healthcare, while Qiming Venture Partners maintains a consistently forward-looking and leading position in healthcare innovation investment, with global rankings persistently within the top five. This powerful collaboration aims to accelerate the commercialization and globalization of China's biopharmaceutical technologies through the S2S platform.
The S2S Symposium is a platform for showcasing curated scientific research. It is an invitation-only event where top scientists can present their entrepreneurial concepts and engage with leading biotech investors.
Following the successful incubation of over 14 startups and the 2024 S2S Japan Symposium, S2S has officially turned its attention to China's scientific community. The inaugural S2S China Symposium aims to build a bridge connecting China's world-class research achievements with top-tier global biopharmaceutical capital. It is committed to unlocking the life sciences potential of China's academic community, providing a showcase stage for early-stage research projects that have not yet received Series A funding or even established legal entities.
For this call for proposals, S2S China seeks breakthrough technologies at the proof-of-concept stage. Ideal candidate projects should feature:
— Novel proprietary academic technology in a therapeutic area
— A path to clinical application within 4–5 years, supported by key data
— Significant advantages over existing therapies (e.g., better addressing unmet clinical needs)
Unlike ordinary pitch events, S2S employs a unique "mentorship" model that pairs selected scientists with venture capital mentors — the two sides collaborate one-on-one to deeply refine entrepreneurial concepts and presentations across novelty, therapeutic potential, and commercialization pathways; selected scientists will have the opportunity to engage directly with world-class investment institutions and industry executives to explore potential investment opportunities, including RA Capital, Qiming Venture Partners, F-Prime, Atlas Venture, Foresite Capital, Lilly Asia Ventures, and Hillhouse; selected scientists will not only gain potential investment opportunities but also the chance to build cross-border partnerships. Additionally, S2S China will provide travel funding for finalists to ensure ideas are presented without barriers.
This is a rare opportunity for direct access to a premier global investment network. We cordially invite top scientists to visit the S2SChina website immediately to submit proposals and embark on an accelerated journey from lab to startup. See you in Hangzhou on October 15, 2026!
Past Highlights
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.